Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Mar-Apr;29(2):137-142.
doi: 10.1177/12034754241302827. Epub 2024 Dec 14.

Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada

Mohannad Abu-Hilal  1 , Jeff Cowger  2 , Mohammed Bawazir  3   4   5 , Dusan Sajic  4   5   6 , Iryna Savinova  7 , Belinda Yap  8 , Rami El-Sayegh  8 , Talshyn Bolatova  8 , Pak Chan  9 , Ajith Cy  4   5
Affiliations
Multicenter Study

Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada

Mohannad Abu-Hilal et al. J Cutan Med Surg. 2025 Mar-Apr.

Abstract

Background: Tildrakizumab is an interleukin-23 inhibitor approved in Canada in 2021 for the treatment of adults with moderate-to-severe plaque psoriasis.

Objectives: To evaluate real-world effectiveness of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis in Canada.

Methods: A multicenter, retrospective study was conducted in Canada in adults with moderate-to-severe plaque psoriasis for ≥1 year treated with tildrakizumab for ≥12 weeks. Effectiveness was evaluated from proportions of patients achieving ≥75%/≥90%/100% improvement from baseline in Psoriasis Area and Severity Index (PASI 75/90/100 response) and Physician Global Assessment (PGA) 0 or 1 at weeks 16 (±4), 24 (±8), and 48 (±12). Subgroup analyses were performed based on prior biologic use and special site involvement.

Results: The study included 75 patients (mean age, 50.5 years; 52.0% female; 82.7% bio-naïve; 73.3% with special site involvement). Absolute mean (standard deviation) PASI score improved from 16.1 (6.7) at baseline to 1.3 (1.7) at the week 48 (91.7% improvement), 95.7%/69.6%/34.8% of patients achieved PASI 75/90/100 response, and 93.0% achieved PGA 0/1 at the week 48. In subgroup analyses, 94.7%/71.1%/34.2% of bio-naïve patients, 100.0%/62.5%/37.5% of bio-experienced patients, 100.0%/71.4%/28.6% of patients with special site involvement, and 81.8%/63.6%/54.6% of patients without special site involvement achieved PASI 75/90/100 response, and 87.5%, 94.3%, 97.0%, and 80.0% of patients, respectively, achieved PGA 0/1 at the week 48. None of the differences among subgroups were statistically significant; however, patient numbers were too small to support robust conclusions.

Conclusions: Tildrakizumab is effective for the treatment of moderate-to-severe plaque psoriasis in adults in a real-world setting in Canada.

Keywords: anti–IL-23; psoriasis; real-world; tildrakizumab.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MAH received advisory board honoraria and consulting fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Hikma Pharmaceuticals, Janssen, LEO Pharma, L’Oréal, Medexus Pharma, Novartis, Pfizer, Sanofi, and Sun Pharma. AC and JC have served on advisory boards, received honoraria, or contributed to clinical trials for AbbVie, Amgen, Aralez Pharmaceuticals, Bausch Health, Celgene Corporation, Eli Lilly, Galderma, Janssen, Johnson and Johnson, LEO Pharma, Novartis, Pfizer, Sanofi, UCB, and Valeant. MB, DS, and IS have no conflicts of interest to declare. BY, RES, and TB are employees of Cencora, Innomar Strategies, Inc. PC is an employee of Sun Pharma Canada Inc.

Figures

Figure 1.
Figure 1.
(A) Mean PASI scores and (B) proportions of patients achieving PASI 75/90/100 responses through week 48. PASI, Psoriasis Area and Severity Index; PASI 75/90/100 response, ≥75%/≥90%/100% improvement from baseline in PASI score; SD, standard deviation.
See this image and copyright information in PMC

References

    1. Menter A, Strober BE, Kaplan DH, et al.. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057 - DOI - PubMed
    1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-212. doi:10.1111/jdv.13854 - DOI - PubMed
    1. Menter A, Gottlieb A, Feldman SR, et al.. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. doi:10.1016/j.jaad.2008.02.039 - DOI - PubMed
    1. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278-285. - PMC - PubMed
    1. Gooderham MJ, Papp KA, Lynde CW. Shifting the focus—the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111-1119. doi:10.1111/jdv.14868 - DOI - PMC - PubMed

Publication types

Substances